Clinical Guides
Hypothyroidism
A clinically focused guide to primary and central hypothyroidism, accurate biochemical interpretation, levothyroxine safety, pregnancy care and Indian follow-up limits.
MedNext Academy | 12 min read
Hypothyroidism
A clinically focused guide to primary and central hypothyroidism, accurate biochemical interpretation, levothyroxine safety, pregnancy care and Indian follow-up limits.
Summary
Hypothyroidism is inadequate thyroid-hormone action. Primary hypothyroidism arises in the thyroid gland and is usually identified by raised TSH with low free T4 when overt; central hypothyroidism arises from pituitary or hypothalamic disease and may have low free T4 with a low, normal or only mildly raised TSH. TSH is therefore an excellent treatment marker in uncomplicated primary disease but can mislead in central disease, non-thyroidal illness, assay interference and early treatment change.
Symptoms such as fatigue, weight change, constipation, low mood, cold intolerance, menstrual change, dry skin and cognitive slowing are common but non-specific. Myxoedema coma is a rare decompensated emergency with altered mental status, hypothermia, bradycardia, hypoventilation or hypotension; treat and investigate simultaneously. Do not label every tired patient hypothyroid, and do not delay emergency sepsis, cardiac, respiratory or hypoglycaemia care while waiting for thyroid tests.
The safe clinical distinction is not merely treated versus untreated. Confirmed overt primary disease, subclinical disease, pregnancy, central disease and decompensated illness each use different biochemical interpretation and escalation. Before attributing an abnormal result to an inadequate prescription, establish the laboratory range, timing of the last dose, product continuity, adherence, food and supplement exposure, acute illness and the possibility of assay interference. A non-elevated TSH is especially unsafe reassurance when pituitary disease is plausible; free T4 and cortisol-risk assessment then take priority.
Pregnancy is a time-critical, separate pathway. ATA pregnancy guidance advises pregnancy-specific TSH interpretation and reports that women already taking levothyroxine may require an early 20% to 30% increase, with testing about every four weeks during the first half of pregnancy. The statement is a verified international recommendation, not a substitute for an Indian obstetric-endocrine plan; local clinicians must confirm the product, starting regimen, testing access and individual cardiac or pituitary risk.
Levothyroxine is replacement, not a weight-loss medicine. Dose and target depend on age, cardiovascular disease, pregnancy, cause, absorption, interactions and adherence. This draft is education only; it does not replace Indian product labels, laboratory reference ranges, pregnancy pathways or endocrinology review.
How Common Is It?
Hypothyroidism is frequently encountered, but prevalence varies with iodine status, age, sex, pregnancy, autoimmunity, laboratory thresholds and screening strategy. A regional survey or treated-clinic denominator cannot honestly become an Indian national estimate. Autoimmune thyroiditis, previous thyroid surgery or radioiodine, neck irradiation, medicines and iodine exposure contribute differently across communities. Population burden is also shaped by access to testing, continuity of levothyroxine supply and whether laboratory reference ranges are locally validated.
Subclinical hypothyroidism means raised TSH with free T4 within the laboratory reference range. It is not synonymous with symptomatic overt disease and may be transient, particularly around non-thyroidal illness or changes in medication and supplements. Prevalence rises with age and changes when a different TSH upper limit is applied. Repeating tests and assessing antibodies, symptoms and progression risk prevents a biochemical finding becoming an automatic lifelong prescription. Pregnancy needs trimester- and assay-specific interpretation; an adult non-pregnant reference range is not a universal pregnancy rule.
Biochemical timing also changes apparent frequency. TSH responds slowly after underreplacement or excess, and a result shortly after a dose change may largely reflect the previous dose. Free T4 needs interpretation with the assay, tablet timing and clinical setting. Severe illness can distort tests; repeat testing after recovery may be safer than escalating therapy unless established disease is convincing. Thyroid antibodies support an autoimmune cause but neither prove that symptoms are hormone-mediated nor set a dose. A low free T4 with low, normal or mildly raised TSH should prompt assessment for pituitary disease rather than reassurance from a non-elevated TSH. [current guidelines, testing recommendations; Endocrine Society 2016, recommendation 1.6]
Risk Factors
Hashimoto thyroiditis, other autoimmune disease, previous thyroidectomy, radioiodine, external neck radiation, postpartum thyroiditis, pituitary disease, iodine deficiency or excess and family history increase probability. Amiodarone, lithium, interferon, immune checkpoint inhibitors and some tyrosine kinase inhibitors can induce thyroid dysfunction. Review supplement use, including biotin, which can interfere with some immunoassays, and iodine-containing contrast or traditional products.
Central hypothyroidism is considered with pituitary tumour or surgery, irradiation, infiltrative disease, traumatic brain injury, postpartum pituitary necrosis, visual symptoms, headaches or other pituitary deficits. In these settings a non-elevated TSH does not reassure when free T4 is low. Evaluate possible cortisol deficiency before giving levothyroxine because thyroid replacement can precipitate adrenal crisis in unrecognised combined pituitary or autoimmune disease.
Pregnancy, infertility and plans for conception need early review because maternal thyroid status and levothyroxine requirements can change. In India, availability of free T4 assays, endocrinology care and pregnancy follow-up varies; ask about supply, tablets bought under different brands, timing with food, iron or calcium, and ability to obtain blood tests. These are practical risk modifiers, not reasons to compromise biochemical safety.
Diagnosis
History
Ask duration and trajectory of symptoms, previous thyroid disease or treatment, surgery, radiation, pregnancy/postpartum timing, menstrual and fertility history, cardiac disease, family autoimmune history, pituitary symptoms, medicines, supplements and how tablets are taken. Specifically ask about iron, calcium, antacids, bile-acid sequestrants, proton-pump inhibitors and food timing because they can reduce absorption. Symptoms of adrenal insufficiency, severe infection or pituitary mass change urgency.
Examination
Record pulse, blood pressure, temperature, weight trajectory, skin, hair, reflexes, proximal strength, oedema, neck scar or goitre, eye signs and cognitive state. Look for bradycardia, hypothermia, pericardial symptoms, neuropathy and features of autoimmune disease. Examine for visual-field loss or cranial-nerve deficits when central disease is possible. No individual sign confirms hypothyroidism; absence of a goitre does not exclude autoimmune or post-treatment disease.
Investigations
For suspected primary disease, measure TSH and free T4 when TSH is abnormal or central disease is possible. Current guidelines recommends TSH as the initial test in adults when secondary thyroid dysfunction is not suspected, with reflex free T4 if TSH is high; use both initially when secondary dysfunction is suspected. Thyroid peroxidase antibodies support autoimmune cause but do not measure dose need. Repeat testing after an adequate interval if illness, biotin, assay interference or transient thyroiditis is plausible. Pituitary hormones and MRI are selected for central disease, not routine primary hypothyroidism.
Differential Diagnosis
Anaemia, depression, sleep disorder, chronic kidney or liver disease, heart failure, diabetes, menopause, medication adverse effects, nutritional deficiency and chronic infection can resemble hypothyroid symptoms. Non-thyroidal illness can lower T3 and sometimes T4 or TSH during severe illness; interpret results with the acute context rather than prescribing replacement for one inpatient panel. Assay interference from biotin or antibodies can produce discordant results.
Primary hypothyroidism is separated from central disease by the relationship of TSH to free T4. A low free T4 with inappropriately non-elevated TSH suggests central disease and demands evaluation for cortisol deficiency and other pituitary pathology. Recovery from thyrotoxicosis, postpartum thyroiditis and some medicines may cause transient abnormalities. Subclinical disease needs repeat confirmation and risk-based decisions, not symptom counting alone.
Myxoedema coma overlaps with sepsis, hypothermia, sedative toxicity, stroke, hypercapnic respiratory failure, adrenal crisis and hypoglycaemia. Goitre or thyroid antibodies do not exclude other causes of deterioration. A raised TSH during inadequate levothyroxine absorption could reflect non-adherence, interaction, malabsorption, wrong product or insufficient dose; it is not evidence that the patient needs an arbitrary large increase without reviewing the mechanism.
Management
Treat overt primary hypothyroidism with levothyroxine using an individualised starting dose and follow-up plan. Younger adults without cardiac disease may start differently from older adults or those with coronary disease, who usually require lower cautious initiation and slower adjustment. Explain empty-stomach administration consistently, separation from iron and calcium, adherence, brand continuity where possible and the delay before a stable TSH response. Titrate from blood tests and clinical state rather than symptoms alone.
For uncomplicated primary disease, monitor TSH after a dose change once steady state is expected; Current guidelines recommends measuring TSH every three months until stable, then annually in adults. In central hypothyroidism, use free T4 and specialist guidance rather than TSH as the primary target. Do not use liothyronine routinely for primary hypothyroidism under current guidelines guidance. Address a cause such as iodine exposure, medicine effect or postpartum disease while maintaining safety.
Pregnancy requires urgent contact with obstetric-endocrine care. ATA recommends pregnancy-specific TSH reference ranges; if unavailable, an upper limit around 4.0 mU/L may be used rather than automatically 2.5. Women taking levothyroxine often need an early dose increase and TSH monitoring about every four weeks in the first half of pregnancy, but exact action follows the current local protocol. Suspected myxoedema coma needs critical-care, intravenous thyroid hormone and glucocorticoid cover under specialist protocol.
Prescribing Information
Use licensed levothyroxine and state the dose, formulation, indication, timing, monitoring test and review date. Take it consistently on an empty stomach according to product instructions; iron, calcium and some antacids should be separated because absorption may fall. Reconcile brand switches, missed doses, enteral feeding, gastric surgery, coeliac disease and interacting medicines before escalating. Do not use thyroid extract, compounded products or liothyronine as routine substitutes for levothyroxine without specialist indication.
Overreplacement can cause palpitations, tremor, insomnia, weight loss, atrial fibrillation and bone loss; underreplacement leaves symptoms and metabolic consequences. Older adults and those with ischaemic heart disease need cautious dosing because excess hormone can provoke angina or arrhythmia. In central disease, ensure glucocorticoid sufficiency first and monitor free T4. In pregnancy, do not stop levothyroxine; check promptly with the pregnancy team.
Exact microgram doses, pregnancy adjustment and paediatric regimens must come from current Indian labels and specialist protocols, not this guide. Check TSH timing before interpreting a recent dose change. Biotin should be discussed with the testing laboratory or stopped according to local assay advice before thyroid function testing. Pharmacist review is useful for polypharmacy, absorption difficulty, repeated abnormal results or supply substitution.
When to Refer
Emergency referral is needed for suspected myxoedema coma, altered consciousness, hypothermia, hypotension, severe bradycardia, hypoventilation, heart failure, pericardial tamponade concern, severe hyponatraemia, hypoglycaemia or adrenal-crisis possibility. Stabilise airway, ventilation, circulation, glucose and temperature gently while arranging critical care and endocrine support; do not manage this as routine outpatient hypothyroidism.
Endocrinology review is appropriate for central hypothyroidism, pituitary symptoms, pregnancy with abnormal tests, persistent abnormal TSH despite confirmed adherence and absorption review, goitre/nodules, treatment intolerance, suspected thyroid hormone resistance, recurrent postpartum disease, children and complex cardiac disease. Obstetric referral is early for pregnancy or conception planning.
Referral should include previous tests with laboratory ranges, doses and brands, administration timing, interacting medicines, pregnancy status, symptoms, examination, antibodies, pituitary concerns and response to changes. In India, facilities without free T4 testing, emergency hormone access or pregnancy-endocrine support should transfer according to urgency. A referral is not a reason to leave a patient without medicine continuity or explicit safety-net advice.
Red Flags
Myxoedema coma features altered mental status, hypothermia, bradycardia, hypotension, hypoventilation, hyponatraemia or hypoglycaemia in severe hypothyroidism, often triggered by infection, sedatives, cold exposure, stroke or heart failure. It is a clinical emergency; thyroid tests support but should not delay critical-care treatment. New chest pain, syncope, severe breathlessness or arrhythmia follows an emergency cardiac pathway.
Headache, visual loss, diplopia, vomiting, collapse, postpartum failure to lactate or other pituitary deficits with low free T4 and non-elevated TSH suggests central disease or pituitary emergency. Features of cortisol deficiency must be addressed before levothyroxine. Pregnancy with significant symptoms or abnormal results needs rapid obstetric-endocrine advice rather than waiting for routine review.
Palpitations, tremor, unexplained weight loss, insomnia or new atrial fibrillation after treatment may indicate overreplacement. Persistently high TSH despite a large reported dose raises absorption, interaction, adherence, assay or diagnostic questions. Safety-net inability to obtain medication, vomiting that prevents tablets, severe lethargy, confusion, low temperature, chest symptoms or pregnancy confirmation. Red flags prompt reassessment, not an automatic dose change by telephone.
Indian Clinical Context
This guide is jurisdictionally Indian but relies on international and ATA guidance, which are not Indian law, formulary or pregnancy protocol. Indian laboratory methods, reference ranges, levothyroxine brands, free T4 availability and referral capacity vary. Clinicians should use local endocrine, obstetric and pharmacy pathways; the NMC document supports education rather than prescribing authority.
Ask about iodine-containing remedies, different tablet brands, cost, supply interruptions, timing with tea, food, iron or calcium, and access to repeat TSH/free T4 testing. Offer clear instructions in the patient’s preferred language and avoid attributing non-adherence to character before resolving formulation or absorption barriers. Pregnancy care must connect to an obstetric service able to monitor both maternal thyroid function and fetal concerns.
No source here supplies a national Indian prevalence or universal pregnancy target. A rural or resource-limited clinic can recognise red flags, maintain proven replacement and arrange referral; it should not attempt complex central disease, myxoedema coma or unmonitored pregnancy adjustment alone. Access uncertainty should be explicit in service design rather than concealed by imported thresholds.
NMC Competency Mapping
NMC CBME 2024 is the Indian undergraduate framework. Hypothyroidism connects thyroid physiology, pituitary feedback, autoimmune pathology, pharmacology, medicine, obstetrics, paediatrics and communication. Exact curriculum codes should be taken from the institutional ledger rather than created for this guide.
Learners should distinguish primary from central biochemical patterns, take a treatment and pregnancy history, recognise myxoedema coma and pituitary warning symptoms, interpret TSH/free T4 in context, identify interactions with levothyroxine and explain why adrenal insufficiency is addressed first when central disease is possible. They should communicate that symptoms alone do not diagnose disease and that medication monitoring is necessary.
Under supervision, a student can counsel on consistent dosing and return tests, document medicine reconciliation and provide a safe referral handover. Students must not prescribe pregnancy adjustments, manage myxoedema coma, independently interpret pituitary imaging or intensify treatment from one result without context. Assessment should contrast overt primary disease, central disease and pregnancy. This mapping does not confer independent practice or publication approval.
Key Exam Pearls for NEET PG
Overt primary hypothyroidism is high TSH with low free T4. Central hypothyroidism is low free T4 with an inappropriately low, normal or mildly raised TSH; TSH cannot guide replacement reliably in central disease. Check cortisol before thyroid replacement when pituitary or combined autoimmune disease is possible.
Levothyroxine is standard first-line replacement. Take it consistently away from iron and calcium; wait for steady state before interpreting a changed dose. TSH guides uncomplicated primary disease, while free T4 guides central disease. Excess causes atrial fibrillation and bone risk; cautious initiation matters in coronary disease. Do not confuse a persistently high TSH with a mandate for a large dose increase: administration timing, product continuity, iron, calcium, acid suppression, malabsorption and missed doses need review first.
Pregnancy uses pregnancy-specific TSH ranges; if absent, ATA permits an upper limit near 4.0 mU/L rather than a universal 2.5 cutoff. Existing levothyroxine often needs early review and increased requirement. Myxoedema coma presents with hypothermia, altered consciousness, bradycardia and hypoventilation: treat in critical care with thyroid hormone and glucocorticoid cover. Subclinical hypothyroidism is raised TSH with normal free T4; repeat confirmation and clinical context matter, while pregnancy has distinct antibody- and threshold-sensitive decisions. [current guidelines, sections 1.4 and 1.5; ATA pregnancy guidance]
Frequently Asked Questions
Can a normal TSH exclude all hypothyroidism?
No. In central hypothyroidism, TSH may be low, normal or only mildly high despite low free T4. Suspected pituitary disease, visual symptoms, postpartum pituitary symptoms or other hormone deficits require free T4 and specialist assessment. In uncomplicated primary disease, however, TSH is usually the main screening and monitoring test. A normal TSH must not dismiss symptoms when pituitary disease is plausible: review free T4, cortisol risk, other pituitary axes, previous cranial treatment and possible assay interference. In critical illness, stabilisation and endocrine discussion may matter more than routine outpatient repeat testing.
Why should levothyroxine not be taken with iron or calcium?
Iron, calcium and some antacids can reduce levothyroxine absorption, causing persistently raised TSH despite an apparently adequate dose. Take the medicine consistently according to product instructions and separate interacting products. Before increasing dose, review timing, brands, missed doses, food, supplements and other medicines. FDA information also identifies bile-acid sequestrants, phosphate binders, proton-pump inhibitors, sucralfate and enteral-feed circumstances as reasons to review absorption or monitoring. First establish a feasible, repeatable timetable; merely doubling the dose may create later overreplacement.
Does subclinical hypothyroidism always need lifelong treatment?
No. It means raised TSH with free T4 in range, and treatment depends on repeat results, TSH level, symptoms, antibodies, age, pregnancy plans and cardiovascular context. Transient illness or assay issues can contribute. A clinician should discuss uncertainty and monitoring rather than start or stop lifelong therapy from one result. Pregnancy and conception planning need a different threshold for action and obstetric-endocrine review. In older adults, potential benefit must be balanced against overtreatment, arrhythmia and fracture risk.
What should a person taking levothyroxine do after confirming pregnancy?
Contact the prescribing clinician or pregnancy team promptly. Thyroid requirements often rise early in pregnancy, and monitoring uses pregnancy-specific interpretation. Do not stop levothyroxine while waiting for advice. The exact dose adjustment and testing schedule should follow the current local obstetric-endocrine protocol. ATA patient guidance describes a commonly used early increase of roughly 20 to 30 percent for women already receiving replacement, followed by prompt testing, but it is not a substitute for a locally prescribed plan. Prenatal vitamins containing iron or calcium also need dose-timing advice.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic